Industry Insider: AI Already Cuts IND Filings by Months and Reduces Animal Studies
nlarusstone · x · 2026-10-17
In a debate over whether AI is really improving biotech R&D, practitioner nlarusstone cites three things seen firsthand: AI has sped up IND filings by months, reduced the number of animal studies needed, and caught errors in critical experiments. He concedes no pharma is fully AI-enabled yet, but argues low-hanging efficiency gains abound; the interlocutor counters that biotech's bottleneck is cost and capital access, with AI ranking far lower.
More from AGI Musings
- 'If I post anything racist it was my dotty': user shows AI agent signed into his X account — JasonBotterill · 2026-10-17
- Anthropic researcher: superposition isn't the blocker, interpretability is more tractable than assumed — adityaag · 2026-10-17
- Dev Claims AI Agents Have No Chance at Real-World Visuomotor Control Design — AlexTensor · 2026-10-17
- AI professor claims universe is a simulation built to create superintelligence, will be 'turned off' — AIFlow_ML · 2026-10-17
- Pedro Domingos: the key AI training data is what you generate by interacting with it — pmddomingos · 2026-10-17
- Productivity is going multiplayer again — this time agent-human-agent in one workspace — aishashok14 · 2026-10-17